Skip to Content

Ropinirole Pregnancy and Breastfeeding Warnings

Ropinirole is also known as: ReQuip Follow on Pack, ReQuip Starter Pack, Repreve, Requip, Requip Starter Kit, Requip XL

Ropinirole Pregnancy Warnings

AU: Use is contraindicated US and UK: This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: May cause fetal harm

In animal studies, this drug was shown to be teratogenic causing adverse effects on embryo-fetal development. In a perinatal/postnatal study in rats using 4 times the mg/m2 maximum recommended human dose, impaired growth and development of nursing offspring and altered neurological development of female offspring were observed. There are no adequate and well controlled studies in pregnant women. AU TGA pregnancy category B 3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Ropinirole Breastfeeding Warnings

Animal studies show that this drug is excreted in the milk of lactating rats. There is no information on use in nursing mothers. As this drug suppresses serum prolactin, it may interfere with breastfeeding. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

AU: Use is contraindicated UK: Not recommended US: Use caution Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: This drug inhibits prolactin secretion and could potentially inhibit lactation.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.